Cyclin-dependent kinase inhibition with roscovitine: neuroprotection in acute ischemic stroke.
Clin Pharmacol Ther
; 91(2): 327-32, 2012 Feb.
Article
en En
| MEDLINE
| ID: mdl-22218073
Stroke is the third most common cause of mortality and the leading cause of disability in industrialized country. According to population based-studies, ischemic stroke accounts for 67-80% of all strokes. Thrombolysis is used during the acute phase in only 2-5% of ischemic patients. Clinical trials of candidate neuroprotective agents have failed to identify viable therapies for ischemic stroke in humans. There is therefore a great need for new therapeutic strategies, considering that not all brain cells die immediately after ischemic stroke.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Purinas
/
Isquemia Encefálica
/
Fármacos Neuroprotectores
/
Quinasas Ciclina-Dependientes
/
Accidente Cerebrovascular
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Clin Pharmacol Ther
Año:
2012
Tipo del documento:
Article
País de afiliación:
Francia
Pais de publicación:
Estados Unidos